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ABSTRACT OF THE THESIS 
 
Predictors of Patient Attendance for Follow-Up Cancer Genetic Counseling Appointments 
 
By 
 
Jessica Elin Spiewak 
 
Master of Science in Genetic Counseling 
 
 University of California, Irvine, 2019 
 
Professor Moyra Smith, MD, PhD, Chair 
 
 
 
Medical providers often interact with and provide care for their patients over the course 
of several visits. In the cancer genetic counseling setting, many patients choose to have genetic 
testing for mutations that confer a heritable predisposition for cancer. Follow-up genetic 
counseling is integral for disclosing genetic testing results and discussing the patient’s cancer 
screening regimen and recommendations for at-risk family members in the context of genetic 
testing results. Previous research has revealed the barriers to an initial cancer genetic counseling 
visit and uptake of genetic testing, but less is known about patients who miss follow-up visits. 
This retrospective chart review compared demographic factors, aspects of patients’ medical 
history, family cancer history, and information covered during genetic counseling for patients 
who had an initial cancer genetic counseling visit in 2016-2017 and attended their scheduled 
follow-up visit to those who missed their follow-up visit. Patient sex, ethnicity, age, personal 
cancer history, initial visit referral indication, type of genetic testing ordered, and proportion of 
first and second-degree relatives affected with cancer did not differ between patients who 
attended and patients who missed their testing results disclosure visit. However, female patients 
x 
 
who had biological children were statistically more likely to attend their follow-up appointment 
compared to childless women, and this trend was present but not statistically significant for men 
who had children compared to childless men. Identifying predictors of follow-up visit patient 
attendance highlights the need for alternate delivery methods in genetic counseling, such as 
written materials, and video or telephone counseling.  
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I. INTRODUCTION 
 
1.1 Cancer genetics 
In 2018, an estimated 1,735,350 Americans were diagnosed with cancer, and 609,640 
died from cancer (SEER Program 2018). Cancer originates from a tumor, which is a growing 
mass of aberrant cells. Tumor cells that have the potential to invade surrounding tissue are 
considered malignant, meaning cancerous, rather than benign. All cancers are caused by 
mutations. Mutations are alterations in the DNA sequence or regulatory elements of a gene that 
disrupt the normal expression of a gene. Mutations accumulate in a person’s cells with time as he 
or she is exposed to different environmental factors, such as UV rays, occupational exposures, 
certain viruses or bacterial infections, tobacco, a high-fat diet, and alcohol. Tumors are often 
caused by accumulated genetic mutations in genes called tumor suppressor genes that normally 
control basic cell growth, proliferation, survival, and DNA repair, thereby preventing abnormal 
cells from developing into a tumor. Biallelic mutations causing loss of function in both copies of 
a tumor suppressor gene in the same cell can lead to tumor development and cancer.  
While all cancers are genetic in origin, they can be classified into one of three types: 
sporadic, familial, and hereditary. Most cancers are sporadic, meaning a person randomly 
accumulated cancer-causing mutations over their lifetime. Sporadic cancers tend to be in 
individuals with an older age of diagnosis who do not have a strong family history of cancer. 
About 20% of cancer is familial, meaning there is a cluster of individuals in the family with 
cancer, but a single inherited genetic predisposition is not identified. Approximately 5-10% of 
cancers are hereditary, meaning they are caused in part by a germline cancer-susceptibility 
mutation that was likely inherited from a parent (Garber and Offit 2005). An individual with an 
inherited cancer syndrome is born with a cancer-predisposing mutation in every cell of his or her 
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body. As such, these individuals have an increased risk to develop cancer. Families with an 
inherited cancer syndrome typically have earlier ages of cancer onset, may include individuals 
with multiple primary tumors, or a rare type of tumor. Some cancer-predisposing mutations 
increase the risk for cancer in several different organs (for example, breast, ovarian, pancreatic 
cancer and melanoma among other types with a BRCA2 mutation), so a family history with 
multiple individuals with related cancers may also suggest a single inherited genetic 
predisposition. Individuals who have personal and/or family history suggestive of a hereditary 
cancer syndrome may qualify for a genetic evaluation and genetic testing, typically performed by 
a cancer genetic counselor.  
 
1.2. Cancer genetic counseling protocol 
 
1.2.1 Cancer genetic counseling discussion points during an initial visit 
 
 Cancer genetic counselors assess a patient’s risk to have a cancer-predisposing mutation 
based on his or her personal medical history and family history. The counselor will explain to the 
patient whether he or she is at risk for a genetic predisposition for cancer, and if genetic testing is 
clinically indicated, the counselor will also explain genetic testing options, risks and benefits of 
testing, and the implications for possible results of testing. This is called pre-test counseling. 
Multiple professional societies including the National Society of Genetic Counselors (NSGC) 
and the American Society of Clinical Oncology (ASCO) recommend pretest counseling (Riley et 
al. 2012; Robson et al. 2015). Discussion between the provider and patient during pretest 
counseling should include: 
• Collection of the patient’s medical history and a three-generation family history. 
Individuals who have a family history of multiple family members with cancer diagnoses, 
one or multiple family members with an early-onset diagnosis, or multiple primary 
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tumors, or diagnosis of a rare cancer may be at increased risk for a cancer predisposition 
syndrome. Additionally, family history of related individuals with the same or related 
cancer diagnoses are likely at increased risk. For example, a patient with who has 
multiple related family members with breast cancer is likely at higher risk to have a 
breast cancer-predisposing mutation than a patient with one family member with a breast 
cancer diagnosis at an average age of onset.  
• Explanation of the patient’s cancer risk based on the patient’s medical and family history, 
which may also include risk assessment through an empiric cancer risk model (e.g. Tyrer-
Cuzick (Tyrer et al. 2004), BOADICEA (Antoniou et al. 2004), BRCAPRO (Parmigiani 
et al. 1998)). There are many different models that calculate the risk for a person to 
develop a specific cancer and/or to have a cancer-predisposing mutation. Traditionally, 
models were based primarily on personal and family history, however some now also 
account for other risk factors such as breast-density and reproductive history (Cintolo-
Gonzalez et al. 2017; Usher-Smith et al. 2016). 
• The utility of genetic testing and appropriate genetic testing options in the context of the 
patient’s personal and family history. 
• Possible results of genetic testing, including 1) positive, meaning a pathogenic mutation 
was detected in a cancer-predisposing gene and there may be recommended changes in 
medical management and cancer screening course, as well as implications for at-risk 
family members 2) negative, meaning no pathogenic mutations were detected in the 
tested genes, and 3) variant of uncertain significance (VUS) was detected, meaning there 
is a difference in the sequence of one of the patient’s genes for which there is not enough 
data to determine whether it is cancer-predisposing or harmless variation. 
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• The possibility for unexpected results, for instance, an identified pathogenic mutation in a 
gene that predisposes to a type of cancer that was previously assessed to be of low 
likelihood based on personal and family history. With the advent of next-generation 
sequencing (NGS) panel testing, many providers offer testing of multiple genes 
simultaneously. While testing more genes can provide more information for the patient, it 
also increases the likelihood of an unexpected result (Desmond et al. 2015; Laduca et al. 
2014; Tung et al. 2015) or a result for which there are unclear medical management 
guidelines (Maxwell et al. 2015).   
• The possibility for an uninformative test result. If a patient has a strong family history of 
cancer, but her cancer NGS panel is negative and there is no known familial mutation, the 
possibility of a genetic predisposition for cancer is not ruled out and she may still be at 
increased risk (Loman et al. 2003). NGS panels cannot detect every possible mutation for 
the tested genes, and there are likely genetic and non-genetic risk factors not tested by the 
panel which may confer risk. Non-genetic risk factors may include a strong family 
history of cancer, breast density (in the context of breast cancer risk), hormonal factors, 
lifestyle factors such as alcohol consumption, smoking, and diet, and polygenic risk 
scores (A. Lee et al. 2019). Polygenic risk scores describe the associated combined 
cancer risk of many single DNA basepairs which are individually correlated with either 
increased or decreased cancer risk. 
• Limits of, and protections granted by the Genetic Information Nondiscrimination Act 
(GINA), (US Congress 2008) which prohibits health insurers from using an enrollee’s 
genetic information to determine coverage, eligibility, or premiums. GINA also prohibits 
employers from discriminating against employees based on genetic information. 
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However, employers with fewer than 15 employees are exempt from the employment 
aspects of GINA, and military medical insurance has a separate, different set of 
protections. 
 
 Pretest genetic counseling in the cancer setting has been shown to have several benefits. 
Women with breast cancer reported increased knowledge of Hereditary Breast and Ovarian 
Cancer syndrome after pretest genetic counseling (Christie et al. 2012; Schlich-Bakker et al. 
2006). Similarly, studies have also shown that individuals at risk for breast cancer have a more 
accurate perception of their risk after cancer genetic counseling (reviewed in Meiser and 
Halliday 2002; Smerecnik et al. 2009), although a few studies with small sample sizes found no 
difference in risk perception accuracy (Pieterse et al. 2006; Rothemund et al. 2001).  
 
1.3 Posttest genetic counseling  
 
After cancer genetic testing is ordered, genetic testing results and the implications of 
those results must be communicated to the patients. Some genetic counselors convey this 
information by phone, while others schedule an in-person follow-up visit with the patient (Wham 
et al. 2010). The role of the genetic counselor in genetic testing results disclosure and posttest 
counseling includes (Riley et al. 2012): 
• Disclose the genetic testing results. 
• Explain the limitations of the genetic test. 
• If the test result is positive, explain the cancer risk and any other medical risks associated 
with the identified mutation. It is also important to discuss any recommended changes in 
cancer screening associated with that mutation, and any prophylactic surgical options if 
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appropriate. For example, if a woman has a mutation in a gene that substantially increases 
her risk for ovarian cancer, a risk-reducing salpingo-oophorectomy (removal of the 
fallopian tubes and ovaries) may be an option (NCCN 2018). For positive results the 
genetic counselor should explain which relatives of the patient are at risk to have the same 
mutation, and also provide materials to help the patient inform his or her relatives (e.x. a 
family letter, referral to genetics clinic). The genetic counselor should also provide 
support resources for the patient.  
• If the test result is negative, explain whether the patient is at any increased risk for cancer 
based on personal and family history alone.  
• If the test result reports a variant of uncertain significance, explain that medical decisions 
are not recommended based on this result because there is currently insufficient evidence 
to determine whether it is cancer-predisposing or harmless variation (Richards et al. 
2015).  
• Answer questions the patient has about the testing and/or cancer screening 
recommendations.  
• The genetic counselor should make referrals as appropriate to providers who can surveil 
high-risk individuals. 
 
In some cancer genetics clinics, patients who have a positive genetic testing result and/or 
a variant of uncertain significance are routinely recommended for follow-up genetic counseling 
6-12 months after their results disclosure appointment. The purpose of a follow-up visit for 
patients with a variant of uncertain significance is for the genetic counselor to determine whether 
the variant has been reclassified as either benign or disease causing, and if so, the implications 
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for medical management and family members. For patients who tested positive on their genetic 
testing, the purpose of a follow-up visit was typically to review testing for family members and 
to further discuss cancer screening for the patient in the context of their mutation.  
 
1.4. Barriers to cancer genetic counseling referrals and uptake 
 
 There are clear guidelines for when patients should be referred for a genetic cancer 
evaluation (Gupta et al. 2017; Hampel et al. 2015; NCCN 2018). Whether a qualified patient is 
referred for cancer genetic counseling depends on both the referring provider’s ability to elicit 
relevant medical history and family history from the patient, and on the provider’s ability to 
determine whether cancer genetic counseling is clinically indicated for that patient. Studies have 
shown that a proportion of general practitioners did not document an adequate family history of 
cancer, and medical documentation often underreported family history of cancer compared to the 
patient’s actual self-reported family history (Grover et al. 2004; Lanceley et al. 2012). Another 
barrier to genetic counseling referral is the lack of awareness of available genetics providers that 
has been reported by some general practitioners, especially in rural areas where the distance to a 
genetics clinic may be greater (Koil et al. 2003; Sweet et al. 2002). Additionally, not every 
patient who is referred to a cancer genetic counselor will choose to meet with one. Having a 
breast cancer diagnosis at a younger age, having female children, and having a high-risk family 
history of cancer are all factors associated with increased uptake for cancer genetic counseling 
(Ayme et al. 2014). It is important that the medical community be aware of and work towards 
lowering the barriers to an initial cancer genetic counseling visit for at-risk patients. 
 
1.5 Predictors for genetic testing uptake 
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 Previous literature has identified predictors of uptake of genetic testing for patients who 
are referred to cancer genetic counseling and are offered genetic testing. Factors associated with 
higher genetic testing uptake for women being evaluated for breast and/or ovarian cancer include 
higher perceived breast or ovarian cancer risk (Andrews et al. 2004), a personal history of breast 
or ovarian cancer (Andrews et al. 2004; Julian-Reynier et al. 2000), having children (especially 
daughters when breast and ovarian cancer are being considered) (Ayme et al. 2014; S. C. Lee et 
al. 2002; Meijers-Heijboer et al. 2000), and having a greater number of relatives affected with 
cancer (Biesecker et al. 2000). Patients who are being evaluated for a genetic risk for colon 
cancer are also more likely to opt for genetic testing if they are personally affected with cancer 
and have more relatives who have had cancer (Codori et al. 1999; Hadley et al. 2003). 
Demographic factors such as the patient’s age and sex have less consistent data regarding 
genetic testing uptake. Some studies have shown significantly increased uptake for women 
compared to men (especially when risk for hereditary breast and ovarian cancer syndrome is 
being considered) (Lerman et al. 1997; Meijers-Heijboer et al. 2000), while others show no 
significant difference (Biesecker et al. 2000; Botkin et al. 2003). Similarly, some studies reveal 
that younger patients are less likely to choose genetic testing during an initial cancer genetic 
counseling visit (Biesecker et al. 2000) while other studies show no significant difference 
(Aktan-Collan et al. 2000; S. C. Lee et al. 2002).  
 
1.6. Aims of this study 
 
The estimated proportion of individuals who do not return for follow-up cancer genetic 
counseling after an initial appointment has not been addressed by currently available published 
literature. Furthermore, which patients are at risk to miss follow-up is unknown. If we can 
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understand the population that is most likely to forgo follow-up appointments, genetic counselors 
can develop methods and tools to ensure posttest recommendations and follow-up care are 
conveyed to at-risk individuals. This retrospective chart reviews aims to collect data on patients 
seen through a cancer genetic counseling service in a university medical center setting over a 
two-year period, in order to: 
 
1. Identify the proportion of individuals who attend an initial cancer genetic counseling 
visit, but do not attend their scheduled follow-up appointment(s).  
2. Identify factors that predict whether a patient will return to their scheduled follow-
up genetic counseling visit. Understanding the group of patients at higher risk to 
miss follow-up appointments can elucidate how to better communicate post-test 
recommendations. I hypothesize demographic factors, personal medical history, 
and the proportion of the patient’s family members who have had cancer are 
predictors of follow-up visit attendance. I will compare these variables between 
individuals who attended their in-person genetic testing results disclosure 
counseling session to those who did not.  
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II. METHODS 
 
2.1. IRB Protocol 
 This research protocol was reviewed by the Institutional Review Board of the University 
of California, Irvine under Exempt Registration HS#2019-4952.  
 
2.2 Retrospective Chart Review  
2.2.1 Patient Chart Selection 
 The initial study population included all patients aged 18 years and older who had an 
initial new-patient consult with a UCI cancer genetic counselor between January 1st, 2016 and 
December 31st, 2017. These cases were identified by reviewing the electronic cancer genetic 
counseling schedule from this time period through the Quest (AllScripts) electronic medical 
record system, used until November 4th, 2017 at UCI, and the Epic electronic medical record 
system from November 4, 2017 through December 2017. This time period ensured that there had 
been at least 16 months since each patient’s initial appointment at the time of data analysis, 
leaving ample time for information from follow-up visits to be included in the dataset. These 
patients were all seen by the same genetic counselor at either the Chao Family Comprehensive 
Cancer Center, University of California, Irvine Medical Center in Orange, CA or the 
Comprehensive Digestive Disease Center, University of California, Irvine Medical Center in 
Costa Mesa, CA. There were 419 patients that met these initial criteria. Within this cohort of 419 
patients, 15 were excluded due to substantial missing information, such as a missing pedigree or 
clinic note for a genetic counseling encounter. The final number of patient charts reviewed in 
this study was 404. Of the 404 patients that qualified for this study, 356 were scheduled for at 
least one follow-up genetic counseling visit, and 291 elected genetic testing during the first 
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appointment. Each patient was given a study ID number that was used for the data collection 
spreadsheet, and the code that links the study ID number to the patient identifier was stored 
separately from the data collection spreadsheet. 
 
2.2.2 Data Collected from Consult Notes in the Electronic Medical Record 
 For each patient chart in this study, demographic information, personal medical history, 
and aspects of the cancer genetic counseling visit were collected from the electronic medical 
record. 
 
Demographic information that was collected from each chart includes: 
• The age of the patient at the time of the initial cancer genetic counseling appointment 
• The sex of the patient reported at the time of the initial cancer genetic counseling 
appointment.  
• The ethnicity of the patient as reported by the patient was collected. Patient ethnicities in 
this study included: 
o Ashkenazi Jewish 
o Asian 
o Black 
o Indian subcontinent, which included Bangladeshi, Indian, and Pakistani 
individuals 
o Hispanic  
o Middle Eastern, which included Afghan, Iranian, and Iraqi individuals 
o White, which means the patient reported European ancestry on both maternal and 
paternal sides of the family 
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o Unknown 
o Mixed, meaning that the patient reported being part of two or more of the 
previous categories.  
• Parent-status of the patient was collected, meaning whether the patient had biological 
children at the time of the initial appointment. If a patient had children, the number of 
male and female children was also noted. 
 
Aspects of each patient’s personal medical history and cancer genetic counseling visit 
information was collected, including: 
• Personal history of cancer as noted in clinic notes and pathology records when 
available in the electronic medical record. The patient’s cancer history at the time of 
the initial genetic counseling appointment was classified as: 
o No history of cancer 
o Current cancer diagnosis 
o Past cancer diagnosis, meaning the patient was considered cancer-free  
o Both a current cancer diagnosis and past cancer diagnosis, meaning the 
patient currently had cancer but also had previously had cancer that had been 
in remission at one point. Patients that had current and past cancer diagnoses 
included individuals who had a recurrence of the same cancer as well as 
individuals who had a new cancer derived from a different primary tumor as 
their past cancer.  
• Other personal medical history that was considered relevant to assessing whether 
someone is at-risk for a hereditary cancer syndrome was collected, including colon 
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polyps, benign tumors, clinical diagnoses of hereditary cancer syndromes such as 
Neurofibromatosis Type I, and precancerous moles.  
• Whether the patient was self-referred or referred by a medical professional to cancer 
genetic counseling was noted. If the patient was referred by a medical professional, 
the specialty of that provider was collected.  
• Primary referral indication was collected for each initial visit. Primary referral 
indication was categorized as either due to personal medical history, family history 
of cancer, or a combination of both.  
• The type of insurance the patient had during the first cancer genetic counseling visit 
was collected. Insurance types included PPO, HMO, Medicare, Medi-Cal 
(California’s state Medicaid program), and Tricare.  
• Whether or not the patient had a family member who had had genetic testing was 
documented, and if that relative was positive for a pathogenic variant in a cancer 
predisposition gene, the gene name was noted.  
• If a patient was referred for cancer genetic counseling and had already had genetic 
testing, the test result was documented. 
• The dates of the initial cancer genetic counseling visit and follow-up visits were 
collected from each patient chart, and the time between visits was calculated. 
• The type of test that was ordered and the test result were both collected for patients 
who previously had genetic testing or had testing during the course of cancer genetic 
counseling. Most patients had a gene sequencing panel of at least two genes, and for 
these patients the type of gene panel was recorded. Other types of genetic testing 
included targeted familial testing, meaning a patient was tested solely for a genetic 
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mutation that was previously identified in a family member. Some patients had single 
gene testing, typically because they had a hereditary cancer syndrome clinical 
diagnosis or there was clinical suspicion for only one type of hereditary cancer 
syndrome.  
• The mode of disclosure of testing results (either by phone or during an in-person 
appointment) was collected.  
• If a patient had been scheduled for a follow-up visit, the reason for doing so as 
documented by the genetic counselor in the previous visit’s clinic note was recorded.   
 
2.2.3 Data Collected from Patient Pedigrees 
 A detailed three-generation pedigree was collected for each patient at every cancer 
genetic counseling initial appointment. For this study, the proportion of adult first-degree, 
second-degree, and third-degree relatives of the patient who had ever been diagnosed with 
cancer, typically by per patient report, was calculated from each family history. First degree 
relatives include parents, full-siblings, and the children of a person. Second-degree relatives 
include half-siblings, aunts and uncles, grandparents, grandchildren, and nieces and nephews. 
The most common third-degree relatives reported were first-cousins, half-aunts and half-uncles, 
great-aunts and great-uncles, and great-grandparents. Some pedigrees did not specify the number 
of individuals in one or more sibships, which was documented as “n” number of individuals on 
the pedigree. Every “n” number of relatives was counted as two relatives, because standard 
pedigree practice is to only use “n” to represent >1 relative; however, there is no maximum 
number of relatives “n” can represent. While assigning “n” the value of two is likely 
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conservative and an underestimate, the average number of relatives “n” truly represents is 
unknown.   
2.2.4 Data Analysis 
 IBM SPSS software version 25 (IBM 2017) was used to calculate both descriptive and 
inferential analyses. Examples of descriptive statistics calculated in this study include the 
frequencies of patient demographic data, basic referral information, and the type of genetic 
testing that was performed. Inferential analyses included comparison of categories within each 
independent variable and the outcome of whether a person attended their follow-up visit. 
Statistical analyses included chi-square analysis or Fisher’s exact test for categorical independent 
variables, and student’s t-test for continuous independent variables. Levene’s test for equal 
variances was employed prior to conducting each t-test. Statistical significance is reported for 
each analysis as a nominal p-value, and a p-value <0.05 was considered significant. For this 
exploratory analysis, no correction was made for multiple comparisons.  
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III. RESULTS 
3.1 Descriptive Data 
Between January 1st, 2016 and December 31st, 2017, 404 new adult patients were seen by 
a UCI cancer genetic counselor and qualified for this retrospective chart review. Of these 404 
patients, 356 were scheduled for a follow-up visit after their initial cancer genetic counseling 
appointment and used for analyses in this study. The majority of patients in this study were 
female (84%), White (43%), Hispanic (20%), or Asian (18%), and were parents to biological 
children (70%) (Table 1 and Figure 1A-C). When categorized by men and women, 73% of male 
patients were fathers and 70% of women were mothers to biological children (Table 1 and Figure 
1C). Most patients had a personal history of cancer, either a current diagnosis (39%), or a 
previous cancer diagnosis (22%) (Table 1 and Figure 1D). Of the total patients, 33% had never 
had cancer and were referred either due to a family history of cancer or due to personal medical 
history such colon polyps (Table 1 and Figure 1D). Most patients were referred to genetic 
counseling by a physician (91%) due to both their personal medical history and family history of 
cancer (61%) (Table 1 and Figure 1E-F).  
Table 1: Patient demographics and referral information of patients scheduled for a follow-
up visit after an initial cancer genetic counseling session at UCI 
  Patient Sex 
                Number    Percent 
  Female 300        84 
 Male 56       16 
 Total (n) 356     100 
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Total Patient Parent-status 
 Number Percent 
 No Children 105 30 
Has Children 251 70 
Total (n) 356 100 
Male Patient Parent-status 
 Number Percent 
 No Children 15 27 
Has Children 41 73 
Total (n) 56 100 
Female Patient Parent-status 
 Number Percent 
 No Children 90 30 
Has Children 210 70 
Total (n) 300 100 
Patient Personal Cancer History 
      Number  Percent  
 Current                139          39 
Previous                  78          22 
Current and Previous                  22           6 
None                117          33 
Total (n)                356        100 
 
 
 
 
 
Table 1 cont. 
Patient Ethnicity 
     Number   Percent 
 
 
 
 
 
 
 
Ashkenazi Jewish                 17       5 
Asian                 63    18 
Black                  5      1 
Hispanic                 71    20 
Indian subcontinent                   5      1 
Middle Eastern                 20      6 
Mixed                 20      6 
Unknown                   1         0.3 
White               154    43 
Total (n)               356  100 
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Table 1 cont. 
Referral Indication 
        Number      Percent 
 Personal history 45               13 
Family history 95               27 
Both 216               61 
Total (n) 356             100 
Referral Source 
            Number  Percent 
 Physician                      324          91 
Self                        31            9 
Total (n)*                      355        100 
*Referral Source was undocumented for one patient. 
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1A) Patient Sex 
 
 
1B) Patient Ethnicity 
 
n=356 
n=356 
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1C) Patient Parent-status 
 
         All Patients 
 
   
      Male Patients         Female Patients  
n=300 n=56 
n=356 
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1D) Patient Personal Cancer History 
 
 
1E) Referral Source for Initial Genetic Counseling Appointment 
 
n=356 
n=355 
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1F) Referral Indication for Initial Genetic Counseling Appointment 
 
 
Figure 1: Frequencies of sex, ethnicity, personal cancer history, referral source, and 
referral indication for the 356 patients that attended an initial cancer genetic counseling 
visit and were scheduled for a return appointment. 1A) The percentage of male and female 
patients included in this study. 1B) There was a range of ethnicities represented in the patients 
that attended an initial cancer genetic counseling session, with the majority being White, 
Hispanic, or Asian. 1C) Most patients in this study were parents to biological children, which 
was true for both male and female patients. 1D) Patient cancer history was categorized as either 
having a current diagnosis of cancer, a previous diagnosis which is no longer in effect, no cancer 
history, or a current cancer diagnosis and previous cancer diagnosis. Patients that qualified as 
having a current and previous diagnosis may have had two different primary cancers, or a 
recurrence of the same cancer. 1E) Patients were either referred to cancer genetic counseling by 
a physician or were self-referred. 1F) The possible referral indications for the initial genetic 
counseling appointment include family history of cancer, personal history only, which includes 
cancer diagnoses and/or other features suggestive of a cancer predisposing mutation such as 
colon polyps, or a combination of both personal medical history and family history.  
  
 
The average age of the patients at the initial cancer genetic counseling visit was 52-years-
old, and the average age of the patients did not differ significantly between men and women 
(t(354 d.f.) =-1.741, p=0.083) (Table 2A and Figure 2A). While the overall mean age did not 
n=356 
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differ between men and women, there is an apparent small peak in the age 25-50 age range 
compared to men (Figure 2B). Therefore, we tested via chi-square analysis whether the number 
of women and men who aged 50 and younger at the initial genetic counseling visit differed from 
the expected frequencies under an assumption of no association between age and sex. 
Categorizing patient-age as 50 and younger and 51 and older is also a clinically important age 
cutoff; NCCN guidelines recommended genetic evaluation for women who have had breast 
cancer at age 50 or younger, which may influence the age distribution of women who are 
referred for cancer genetic counseling. However, chi-square analysis found no significant 
association in this sample between age (categorized as 50 or younger versus 51 and older) and 
sex (χ2 (1 d.f.) =2.288, p=0.130) (Table 2B). 
 
Table 2: Age distribution for male and female patients who attended an initial visit and 
were scheduled for a follow-up visit 
 
Table 2A 
Mean Age of Patient by Sex  
Sex Mean N Std. Dev.  
Female 51.7 300 14.7  
Male 55.4 56               13.5  
Total (n) 52.3 356 14.5  
t (354 d.f.) =-1.741, p=0.083 
 
Table 2B 
Patients over age 50 by Sex 
 
Sex 
Total Female Male 
Age >50 161 36 197 
≤50 139 20 159 
Total (n) 300 56 356 
χ2 (1 d.f.) =2.288, p=0.130 
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2A) Age Distribution of Patients 
 
 
2B) Age Distribution of Patients by Sex 
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Figure 2: Age distribution of patients who attended an initial visit and were scheduled for a 
follow-up visit. 2A) The mean age of the 356 patients who attended an initial cancer genetic 
counseling visit and were scheduled for follow-up is 52.3 years old. 2B) The age distribution of 
male and female patients was determined to be of equal variance and equal means. 
 
 
 Most of the patients seen during this period had cancer genetic testing during their initial 
cancer genetic counseling visit or came to their initial visit having already had cancer genetic 
testing. Most patients had gene panel testing (80%) (Table 3A and Figure 3A). The biggest 
proportion of panels were broad and targeted cancers of different organs (“multi-organ”), and the 
next most common panel ordered targeted breast cancer-related genes (23%) (Table 3B and 
Figure 3B). Approximately 7% had site-specific mutation testing, meaning testing for only one 
mutation in one gene (Table 3A and Figure 3A). These patients typically had a family member 
who had a known cancer-predisposing mutation and were being tested for that same mutation 
only (Appendix A). About 3% of patients had testing for only one gene, typically because their 
personal history and/or family history were consistent with one syndrome caused by mutations in 
only one gene (Table 3A and Figure 3A). For example, individuals with history of 
retinoblastoma and no other personal or family history of cancer were offered RB1 testing 
because there are no other genes known to be associated with retinoblastoma at this time 
(Appendix B). A small proportion of patients who had a follow-up visit scheduled after an initial 
cancer genetic counseling session did not have genetic testing during or before the first visit 
(9%) (Table 3A and Figure 3A). Some of these patients did not have genetic testing because 
there was a different family member who would be more informative to test first, either because 
that person had a cancer history or was more closely related to an individual with cancer than our 
patient was. In these cases, the patient was scheduled to return to clinic after his or her family 
member underwent genetic counseling and possibly genetic testing, or after it was determined 
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that the family member was not going to proceed with genetic counseling or testing. Other 
patients who did not have genetic testing during or before their initial visit may have been 
missing critical records, such as past genetic testing results or the testing results of a family 
member. These patients were asked to bring these results to a follow-up visit during which 
genetic testing may be offered, understanding that testing could proceed without obtaining the 
previous testing results, but that testing would most likely be more informative if results from an 
affected family member were available.  
 
 
Table 3: The type of genetic testing patients had either before their initial visit or ordered 
during their first genetic counseling appointment 
 
Table 3A 
Type of Genetic Test Ordered 
 Number Percent 
 Site-specific mutation† 25         7 
None 33         9 
Panel‡ 282       80 
Single Gene 11         3 
Total (n)* 351     100 
*Type of genetic test was undocumented for 5 patients.  
† “Site-specific mutation” refers to testing one mutation in one  
gene, typically one previously identified in a family member.  
‡ “Panel” testing means testing of at least two genes.  
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Table 3B 
Type of Gene Sequencing Panel Ordered 
 Number Percent 
 Breast 64        23 
Colon 24          9 
Multi-organ* 91        32 
Melanoma 4          1 
Ovarian 37        13 
Ovarian and Uterine 47        17 
Pancreatic 2             0.7 
Paraganglioma 1             0.4 
Prostate 1             0.4 
Renal 10          4 
Uterine 1             0.4 
Total (n) 282           100 
*“Multi-organ” refers to broad panels that include multiple  
cancer sites and syndromes that are unrelated.  
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3A) Type of Genetic Testing Ordered 
  
 
 
 
 
3B) Type of Gene Panel Ordered 
 
 
n=356 
n=282 
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Figure 3: Type of genetic testing ordered for patients who attended an initial cancer genetic 
counseling visit and were scheduled for a follow-up visit. 3A) Patients had either no genetic 
testing, panel testing (meaning two or more genes were tested concurrently), single gene testing, 
or targeted familial variant testing (meaning testing for one mutation that had been identified 
previously in a family member). 3B) There were multiple types of genetic testing panels utilized 
for the 282 patients that had panel testing. Panels typically included genes in which mutations 
cause a particular type of cancer, however some were broader (“multi-organ”). 
 
 
3.2 Analyses of factors hypothesized to predict patient follow-up visit attendance 
 During 2016 and 2017, there were 291 patients who were offered and elected to have 
cancer genetic testing at their initial visit, the results of which were to be disclosed at a follow-up 
visit. Of these patients, 225 attended their scheduled results disclosure visit (225/291 = 77%). Of 
the 225 patients who attended  their scheduled results disclosure visit, 82 were scheduled for 
another follow-up visit to further discuss whether there were updates in medical management 
and/or family testing recommendations due to a cancer-predisposing mutation, or to discuss 
whether there was updated information on a variant of uncertain significance that had been 
detected on testing. There was a large drop-off in attendance between the results-return follow-
up visit and the next return visit, with a 17% attendance rate (14/82) (Figure 4, Row A). For the 
82 patients scheduled for an additional follow-up appointment, the reasons for this appointment 
as documented by the genetic counselor were either to discuss whether there was an update in 
variant of uncertain significance classification (37/82 = 45%), whether there were updates in 
cancer screening and medical management for patients with a cancer-predisposing mutation 
(20/82 = 25%), or another reason such as discussing the possibility of additional genetic testing 
or revisiting the topic of testing relevant family members (25/82 = 30%) (Figure 5).   
There were 33 patients in the study period that did not have genetic testing ordered 
during or before the first genetic counseling visit. These patients intended to get more 
information from a family member, such as their genetic testing results before proceeding with 
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testing themselves. If they were unable or unwilling to coordinate with their family, genetic 
testing was typically offered to them. All 33 of these patients were scheduled for a return visit, of 
which 10 attended (30%) to revisit genetic testing (Figure 4, Row B).  
Another alternate genetic counseling track included 32 patients who already had genetic 
testing ordered and the results disclosed by another provider by the time of the initial cancer 
genetic counseling visit. The purpose of their initial visit with the genetic counselor was to 
discuss the implications of a positive genetic testing result or a detected variant of uncertain 
significance. These patients were all scheduled for a follow-up genetic counseling visit to further 
discuss the personal and familial implications of their positive genetic testing or to discuss any 
updated variant of uncertain significance information. Of these of 32 patients, 8 attended (25%) 
their follow-up cancer genetic counseling appointment (Figure 4, Row C).  
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4) Cancer Genetic Counseling Visit Tracks and Attendance Rates 
 
Figure 4: The number of patients who attended initial cancer genetic counseling visits and 
follow-up visits. There are typically three possible visit tracks that each cancer genetic 
counseling patient underwent during the study period. Most patients followed track A, in which 
the patient was offered genetic testing by the genetic counselor based on analysis of the patient’s 
personal and family history, and the patient elected testing and had a sample drawn the same day. 
A follow-up appointment to disclose and discuss the genetic testing results was scheduled for 
one month after the initial visit. 82 of the patients who attended their results return appointment 
were scheduled for another follow-up visit 6-12 months later, typically because the patient was 
positive for a cancer-predisposition gene and personal and family management guidelines were 
to be discussed at the next visit, or because the patient had a variant of uncertain significance 
(VUS) and updated information and classification status were to be discussed. Patients on track 
B did not have a sample drawn for genetic testing at the first genetic counseling visit, usually 
because they were not the ideal candidate for testing in the family or additional records were 
needed before ordering testing such as a family member’s testing results. These patients were 
scheduled for a follow-up visit 2-6 months later to re-evaluate the possibility of genetic testing 
once the patient gathered more information or if it was determined that the patient would not be 
able to gather more information. Patients who followed track C came to the initial cancer genetic 
counseling appointment having already had genetic testing through a different provider and were 
referred to further discuss implications of the test results for personal medical management and 
for family members. All 32 of these patients were scheduled for a follow-up appointment in 6-12 
months to further discuss medical recommendations based on the patient’s positive test result, or 
possible reclassification of a variant of uncertain significance result. The number of patients who 
attended each type of visit is shown in bold.   
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5) Stated Reason for Recommended Follow-up Visit after Genetic 
Testing Results Disclosure Visit 
 
 
Figure 5: Referral indications for a cancer genetic counseling follow-up visit after the 
results disclosure visit.  Of the 291 patients who attended their genetic testing results disclosure 
visit, 82 were recommended by the genetic counselor to have another follow-up visit. The 
documented reasons for the follow-up visit include reviewing whether there is an update in 
classification status of a variant of uncertain significance, reviewing whether there are updated 
medical management guidelines for the patient’s cancer-predisposing mutation, or for other 
reasons which include but are not limited to discussing genetic testing for family members or 
additional testing options for the patient. 
 
To determine predictors of whether a patient is at high-risk to miss their follow-up visit, 
we compared demographics, personal medical history, and family cancer history among patients 
who attended and patients who missed their results disclosure visit after an initial cancer genetic 
counseling visit. Patients who previously had genetic testing ordered by another provider and 
those who did not have genetic testing ordered at the initial visit were excluded because these 
small populations of patients may have very different motivations for returning to clinic 
VUS Status
Update
Management
Other
30% 
45% 
25% 
n=82 
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compared to those who are returning to receive and discuss their genetic testing results. Of the 
291 patients scheduled for a results disclosure visit, 77% of patients (225/291) attended and 23% 
of patients missed their appointment, and therefore received their results by another mechanism 
(either by phone call, or from their referring provider (66/291) (Figure 6).  
 
6) Results Disclosure Visit Attendance 
 
 
 
 
Figure 6: Attendance frequency for results disclosure return visits. Of the 356 patients who 
attended an initial cancer genetic counseling appointment during the study period, 291 had a 
sample drawn for genetic testing at the first visit. 77% of those patients attended their results-
disclosure follow-up visit, and 23% did not attend their scheduled visit. 
 
  
 Demographic information that was collected and compared amongst patients who 
attended and missed their results disclosure visit include the sex, ethnicity, and age of the patient. 
Chi-square analysis showed there was no significant difference in the attendance rate for the 
genetic testing results disclosure visit for between men and women (χ2 (1 d.f.) =0.173, p=0.677) 
n=282 
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(Table 4A and Figure 7A). Additionally, there was no difference in individuals of Asian, 
Hispanic, and White ethnicity (other ethnicities did not have a large enough sample size for 
statistical analysis) (χ2 (2 d.f.) =2.371, p=0.306) (Table 4B and Figure 7B). The median age for 
patients who attended their appointment was 57 years and the range was 65 years, from age 20 to 
85 years-old. The median age was 54 years for patients who missed their appointment and range 
was 69 years, from age 18 to age 87 years-old (Figure 8). The mean age for those who attended 
their results disclosure visit (53 years) and those who missed the appointment (56 years) was not 
statistically different (t(289 d.f.) =-1.325, p=0.186) (Table 4C). These results suggest the 
patient’s sex, ethnicity, and age are not predictive of whether they will attend their genetic 
testing results disclosure appointment. 
Table 4: Demographic factors of patients who attended and who missed results their results 
disclosure visit 
  
Table 4A 
Results Return Attendance by Patient Sex  
 
Results Disclosure Visit Attendance 
Total Attended Percent 
Sex Female 186 77 242 
Male 39 80 49 
Total (n)  225  291 
χ2 (1 d.f.) =0.173, p=0.677 
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Table 4B 
Results Return Attendance by Patient Ethnicity 
 
Results Disclosure Visit Attendance 
Total Attended Percent 
Ethnicity Asian 38 83 46 
Hispanic 45 80 56 
White 94 73 129 
Total (n)* 177  231 
χ2 (2 d.f.) =2.371, p=0.306 
*Ashkenazi Jewish, Black, Indian subcontinent, Middle Eastern, 
mixed, and unknown ethnicities were excluded because of 
insufficient sample size for chi-square analysis. 
 
 
Table 4C 
 Results Disclosure Visit Attendance by Age of Patient   
 Results Disclosure Visit 
Attendance N Mean Std. Dev. 
Age Attended 225 53.4 14.0 
Missed 66 56.0 15.2 
t(289 d.f.) =-1.325, p=0.186 
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7A) Results Disclosure Visit Attendance Rates by Patient Sex 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
77% 
80% 
20% 23% 
         (n=242)    (n=49) 
Sex of the Patient χ2 (1 d.f.) =0.173, p=0.677 
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7B) Results Disclosure Visit Attendance Rates by Patient Ethnicity 
 
 
 
 
 
Figure 7: Comparisons of patient sex, ethnicity, and mean ages of age for patients who 
missed and who attended their results disclosure visit 7A. Chi-square analysis found that the 
attendance rate between men and women was no different than expected. 7B. Chi-square 
analysis determined results disclosure attendance did not differ between different ethnicities 
from the expected attendance rate.  
  (n=46)           (n=56)         (n=129) 
Ethnicity of the Patient 
χ2 (2 d.f.) =2.371, p=0.306 
17% 
83% 
20% 27% 
73% 
80% 
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8) Patient Age Distribution by Results Disclosure Attendance 
 
 
 
Figure 8: The distribution of ages of patients who missed and patients who attended their 
results disclosure visit. The medians are represented by the black line in the middle of each box, 
54 years for the attended visit group, 57 years for the missed visit group. Each box represents the 
25th to the 75th percentile age range. The bars represent the minimum and maximum values with 
the exception of one outlier (green dot), which is defined as any value 1.5 box lengths from the 
median. 
 
 To determine whether there is a relationship between the patient’s personal experience 
with cancer and cancer genetic testing and results disclosure visit attendance, we preformed chi-
square analysis to compare patients who attended their visit to those who missed their visit. A 
reasonable hypothesis might be that a patient who has a personal history of cancer would be 
more likely to attend his or her results return visit, perhaps out of a greater concern or perceived 
risk for a cancer-predisposing mutation; however, chi-square analysis found no significant 
difference in attendance rate in patients who currently have cancer (81% attended), who 
previously had had cancer (76% attended), and who have never had cancer (73% attended) 
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(Table 5 and Figure 9A) (χ2 (2 d.f.) =1.820, p=0.403). Similarly, results disclosure attendance 
rate did not differ between different referral indications for the initial cancer genetic counseling 
visit. 85% of patients who had been referred due to their personal medical history attended their 
results disclosure visit, compared to 76% of patients who were referred due to family history, 
and 77% of the patients referred due to both a personal and family history (χ2 (2 d.f.) =1.221, 
p=0.543) (Table 5 and Figure 9B). Additionally, the type of genetic test that was ordered either 
prior to the initial genetic counseling visit or during the first visit does not appear to influence 
results disclosure attendance (χ2 (1 d.f.) =0.052, p=0.820) (Table 5 and Figure 9C).  
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Table 5: Frequencies of personal medical history factors of patients who attended 
and who missed results their results disclosure visit.   
 
Results Disclosure Attendance by Patient Personal Cancer History 
 
Results Disclosure Visit Attendance 
Total Attended Percent 
Cancer history Current* 109 81 135 
Previous 56 76 74 
None 60 73 82 
Total (n) 225  291 
χ2 (2 d.f.) =1.820, p=0.403 
*Individuals who had both a current and previous cancer diagnosis were included in 
the current category for this analysis.  
 
Results Disclosure Attendance by Referral Indication 
 
Results Disclosure Visit Attendance 
Total Attended Percent 
Referral indication Personal History 28 85 33 
Family History 50 76 66 
Both 147 77 192 
Total (n) 225  291 
χ2 (2 d.f.) =1.221, p=0.543 
 
Results Disclosure Visit Attendance by Genetic Testing Type Ordered   
 
Results Disclosure Visit Attendance 
Total Attended Percent 
Test type Panel 200 81 258 
Targeted* 25 73 33 
Total (n) 225  291 
χ2 (1 d.f.) =0.052, p=0.820  
* ”Targeted” testing includes both single gene testing and site-specific mutation testing. 
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9A) Results Disclosure Visit Attendance by Patient Cancer History 
 
 
 
 
 
  
  (n=135)            (n=74)          (n=82) 
Patient Cancer History 
χ2 (2 d.f.) =1.820, p=0.403 
19% 
81% 
24% 27% 
73% 76% 
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9B) Results Disclosure Visit Attendance by Referral Indication 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   (n=33)              (n=66)           (n=192) 
Patient Cancer History 
χ2 (2 d.f.) =1.221, p=0.543 
15% 
85% 
24% 23% 
77% 
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9C) Results Disclosure Visit Attendance by Genetic Testing Type 
 
 
 
 
 
Figure 9: Comparisons of patient personal cancer history, referral indication, and type of 
genetic testing for patients who missed and who attended their results disclosure visit 9A) 
Chi-square analysis showed that the attendance rates for patients who had a current cancer 
diagnosis, a previous diagnosis, or had never had cancer did not differ. 9B) Referral indication 
for the initial cancer genetic counseling visit did not influence results disclosure visit attendance 
rate according to chi-square analysis. 9C) There was no difference in attendance rate for 
individuals who had targeted testing compared to those who had gene panel testing, defined as 
testing of two or more genes concurrently. Targeted testing in this analysis includes both 
individuals who had single gene testing and those with targeted familial mutation testing.  
 
 
The potential genetic risk to a patient’s children led to the hypothesis that cancer genetic 
counseling patients who are parents were more likely to have attended their results disclosure 
visit. Chi-square analysis revealed that patients who have children were more likely to attend 
their results disclosure visit than patients who do not have children (χ2 (1 d.f.) =6.896, p=0.009) 
27% 
73% 
81% 
19% 
          (n=258)                  (n=33) 
Genetic Testing Type 
χ2 (1 d.f.) =0.052, p=0.820 
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(Table 6 and Figure 10A). When parent-status was analyzed separately by sex, mothers were 
more likely to attend their results disclosure visit than women who did not have children 
(p=0.01). There was no statistically significant difference in the likelihood for fathers to attend 
their appointment, in comparison to men who did not have children (Fisher’s Exact p = 0.442).  
However, the direction of this relationship is in the same direction as for mothers (Table 6 and 
Figure 10B-C); because of the sample size, there was limited power to investigate this 
relationship in the male sample.  
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Table 6: Frequencies of parents and individuals without children who attended and 
who missed results their results disclosure visit 
 
Results Disclosure Attendance for Patients by Parent-Status 
 
Results Disclosure Visit Attendance 
Total Attended Percent 
Parent-Status No Children 52 67 78 
Has Children 173 81 213 
Total (n) 225  291 
χ2 (1 d.f.) =6.896, p=0.009 
 
Results Disclosure Attendance for Female Patients by Parent-Status 
 
Results Disclosure Visit Attendance 
Total Attended Percent 
Parent-Status No Children 42 66 64 
Has Children 144 81 178 
Total (n) 186  242 
χ2 (1 d.f.) =6.175, p=0.013 
 
Results Disclosure Attendance for Male Patients by Parent-Status 
 
Results Disclosure Visit Attendance 
Total Attended Percent 
Parent-Status No Children* 10 71 14 
Has Children 29 83 35 
Total (n) 39  49 
Fisher’s Exact p=0.442 
*One cell had an expected count less than 5 for statistical analysis. The minimum 
expected count was 2.86.  
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10A) Results Disclosure Visit Attendance by Parent-status 
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χ2 (1 d.f.) =6.896, p=0.009 
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10B) Results Disclosure Visit Attendance for Female Patients by 
Parent-status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
66% 
34% 19% 
81% 
            (n=64)                    (n=178) 
Patient Parent-Status 
χ2 (1 d.f.) =6.175, p=0.013 
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10C) Results Disclosure Visit Attendance for Male Patients by 
Parent-status 
 
 
 
 
 
Figure 10: Comparisons between patients who attended and missed their results disclosure 
visit by whether they have children 10A) Chi-square analysis revealed that patients who are 
biological parents were more likely to attend their results disclosure appointment than expected 
10B) Chi-square analysis showed that the higher-than-expected attendance rate was upheld in 
female parents. 10C) Fathers were more likely than men without biological children to attend 
their results disclosure, but this result is not statistically significant. 
 
 
 Because a strong family history of cancer increases a patient’s risk to have a hereditary 
cancer syndrome, it was hypothesized that patients who had a greater number and greater 
proportion of closely related relatives with cancer history would be more likely to attend their 
results-disclosure visit. The mean total number of first-degree relatives for each patient was 
approximately 6 relatives, with a minimum of 1 relative and maximum of 19. The mean number 
71% 
29% 
83% 
17% 
            (n=14)                     (n=35) 
Patient Parent-Status 
Fisher’s Exact p=0.442 
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of affected first-degree relatives for patients who attended their appointment was 1.3 relatives 
compared to 1.5 relatives for those missed their appointment. The mean number of affected first-
degree relatives was not significantly different between patients who attended and patients who 
missed their results disclosure appointment (t(289 d.f.) =-0.991, p=0.332) (Table 7 and Figure 
11A). The mean total number of second-degree relatives was approximately 13 people, with a 
minimum of 0 relatives and maximum of 40 relatives. The average number of affected second-
degree relatives for patients who attended their appointment was 1.9 relatives, and 2.2 second-
degree relatives for patients who missed their appointment which is not significantly different 
(t(289 d.f.) =-1.077, p=0.283) (Table 7 and Figure 11B). Additionally, the mean proportion of 
affected first-degree relatives and of affected second-degree relatives did not differ between 
patients who attended and patients who missed their results-disclosure visit (t(289 d.f.) =-1.153, 
p=0.250 for first-degree relatives, t(88.8 d.f.) =-1.598, p=0.114 for second-degree relatives) 
(Table 8 and Figure 12). These data suggest the number of and proportion of first and second-
degree relatives who had a reported cancer history did not significantly impact the results 
disclosure attendance rate.  
 
Table 7: Mean number of first and second-degree relatives of the patient that reportedly 
have had cancer 
 
 Second Visit Attendance N Mean 
Number First-degree 
Relatives Affected 
Attended 225 1.3 
Missed 66 1.5 
Number Second-degree 
Relatives Affected 
Attended 225 1.9 
Missed 66 2.2 
First-degree relatives: t(289 d.f.) =-0.991, p=0.332 
Second-degree relatives: t(289 d.f.) =-1.077, p=0.283 
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11A) Number of First-degree Relatives in Each Patient’s Family 
 
 
 
 
11B) Number of Second-degree Relatives in Each Patient’s Family 
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Figure 11: The number of first and second-degree relatives in each patient’s family. 11A) 
The mean total number of first-degree relatives reported by patients at the initial cancer genetic 
counseling appointment. 11B) The mean total number of second-degree relatives reported by 
patients at the initial cancer genetic counseling appointment. 
 
 
Table 8: Mean proportion of first and second-degree relatives of the patient that reportedly 
have had cancer 
 
 Second Visit Attendance N Mean 
Proportion First-degree 
Relatives Affected 
Attended 225 0.24 
Missed 66 0.27 
Proportion Second-degree 
Relatives Affected 
Attended 225 0.16 
Missed 65 0.20 
First-degree relatives: t(289 d.f.) =-1.153, p=0.250 
Second-degree relatives: t(88.8 d.f.) =-1.598, p=0.114 
 
12A) Distribution of Proportion of Affected First-degree Relatives 
by Results Disclosure Visit Attendance 
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12B) Distribution of Proportion of Affected Second-degree Relatives 
by Results Disclosure Visit Attendance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: The proportion of first and second-degree relatives affected with cancer. 12A) 
The distribution of reported first-degree relatives with cancer history. 12B) The distribution of 
reported first-degree relatives with cancer history. Black lines represent the median proportions, 
and the boxes signify the 25th to 75th percentiles for proportion of affected relatives. The bars 
represent the minimum and maximum values, except for outliers (dots), which are values 1.5 box 
lengths from the median. 
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IV. DISCUSSION 
 Medical providers often interact with their patients across multiple visits rather than 
simply a first visit to clinic. In the context of cancer genetic counseling, follow-up visits may 
involve genetic testing results disclosure, discussion of how a patient’s medical management 
should change based on testing results, recommendations for cancer screening and prevention, 
and coordinating genetic testing for at-risk family members. However, with each scheduled 
follow-up appointment for a patient, there is a possibility that the patient does not attend that 
visit and as a result loses the opportunity to discuss critical personal and family health 
recommendations. The aim of this retrospective chart review was to identify the attendance rate 
of cancer genetic counseling follow-up visits from patients at UCI that had an initial visit in 2016 
or 2017, and to identify factors that differed between patients who attend and patients who miss 
these visits. Understanding which patients are more likely to miss their follow-up visits can help 
genetics providers identify at-risk patients who may require a different method or timeline in 
communicating critical health information.  
  
4.1 Cancer genetic counseling follow-up visit attendance rates  
 This study recorded visit attendance for patients who had an initial cancer genetic 
counseling visit between January 1st, 2016, and December 31st, 2017. All patients saw the same 
genetic counselor. Of the 356 patients who qualified for this study, 291 had genetic testing 
ordered during their initial cancer genetic counseling visit and were scheduled for a follow-up 
visit to receive the test results and discuss the personal and family medical implications. This 
study found that 225 of these patients attended their results disclosure visit (77%), and 66 
patients missed their appointment (23%) (Figure 4 and Figure 5). Of the 225 patients who 
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attended their results disclosure visit, 82 were recommended to have another follow-up visit 6-12 
months later typically to discuss whether there were updated medical management guidelines for 
the patient’s positive genetic testing result or to check for updates in the classification status of a 
variant of uncertain significance identified on genetic testing. Of these 82 patients, 14 attended 
their follow-up visit (17%), which was a surprisingly low percentage. This subset of patients was 
not large enough to perform statistical analyses to compare the predictors of those who missed 
and those who attended their follow-up visit. However, all of these patients had either a positive 
result on genetic testing, meaning they had detectable mutation in a gene that increases their risk 
for cancer, and/or a variant of uncertain significance, meaning a genetic variant was detected, but 
data at the time of the test report was insufficient to classify it as cancer-predisposing or harmless 
variation. Each of these patients had a clinical indication to return for follow-up as determined by 
their cancer genetic counselor (Figure 5). It is likely that a proportion of these patients received 
medical management updates from a non-genetics provider they routinely see, however this 
study did not calculate how many patients fit this description and did not record what was 
discussed at relevant appointments with non-genetics providers. 
 Current literature supports the need to inform patients of reclassification of their variants 
of uncertain significance on genetic testing. Variants of uncertain significance are common, and 
the likelihood of a variant of uncertain significance result depends on the number of genes tested, 
how well-established in scientific literature a gene is, the ethnicity of the patient (Easton et al. 
2007; Nanda et al. 2005; Ricker et al. 2016), and the variant classification methodology used by 
the testing laboratory. A recent study that reviewed cancer genetic testing results from 2006-
2016 for over 1.5 million patients through one genetic testing laboratory showed that 18.7% of 
multigene panels were negative but had at least one reported variant of uncertain significance 
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(Mersch et al. 2018). Within the time period, 25% of the reported variants of uncertain 
significance were reclassified to either pathogenic or benign. While most of these variants of 
uncertain significance were reclassified as benign (91%), 9% were reclassified to pathogenic 
(Mersch et al. 2018), which is a rate consistent with previous literature (Macklin et al. 2018). For 
some patients, particularly those with less education, a variant of uncertain significance in a 
cancer predisposing gene causes anxiety or frustration, (Hallowell et al. 2002; Lumish et al. 
2017; O’Neill et al. 2009; Richter et al. 2013) which could be alleviated by being informed that it 
has been reclassified as benign. For cases in which a variant of uncertain significance is 
reclassified to pathogenic, the impact is more obvious; medical management is often altered in 
order to prevent or detect cancer at an early stage when a patient has a known cancer-
predisposing mutation. At-risk family members can pursue genetic testing for the known 
mutation and have a similarly personalized cancer screening course based on their targeted test 
result. While the benefits of informing patients of reclassified variants of uncertain significance 
are clear, there is disagreement on who has the responsibility to inform the patient as it may take 
years for a variant to be reclassified (Hoffman-Andrews 2017; Murray et al. 2011; Otten et al. 
2015). In that time, a patient may have changed their phone number, address, and/or primary 
care physician, making it difficult for the original genetics providers or genetic testing lab to 
reconnect with the patient. A scheduled in-person follow-up visit with the genetic counselor to 
discuss any potential updates in variant status may be one strategy to better maintain open lines 
of communication. Yet, the results of this study showed that a large proportion of individuals 
scheduled for these types of follow-up visits did not attend their appointment, and the few who 
did attend their appointment had no change in variant status at the time of the follow-up visit.  
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Emerging alternate models of genetic counseling may be a reasonable way for some 
clinics to bypass the barriers specific to in-person follow-up visits. For example, telegenetic 
counseling uses videoconferencing to connect a genetic counselor and a patient, and genetic 
counseling by telephone is becoming increasingly common (Bradbury et al. 2011; Peshkin et al. 
2016). The National Society of Genetic Counselors has practice guidelines for cancer genetic 
counselors that include what should be addressed during genetic testing results disclosure. The 
guidelines acknowledge that some genetic counselors routinely disclose result in-person and 
others do so by telephone, but do not expressly recommend one method over the other (Riley et 
al. 2012). A few studies have compared patients who had cancer genetic counseling via 
telephone to those who had in-person sessions found that patients in these two groups did not 
differ in their anxiety, cancer-specific psychological distress, or decisional regret and overall 
satisfaction, but fewer patients elected genetic testing after telephone genetic testing compared to 
in-person visits for unknown reasons (Kinney et al. 2014; Peshkin et al. 2016). Unsurprisingly, 
cancer genetic testing patients reported that telephone counseling was more convenient than in-
person sessions (Peshkin et al. 2016). In-person initial cancer genetic counseling visits with an 
option for follow-up appointments via telephone may be one way to maintain genetic testing 
uptake while also providing a more convenient way for patients and providers to discuss follow-
up concerns such as updated medical management, family member testing, and variant of 
uncertain significance updates. However, this may not a realistic strategy for all genetic 
counselors because some insurance companies do not cover telegenetic or telephone counseling, 
and there may be specific limitations depending on the medical institution. 
 
4.2 Factors influencing genetic testing results disclosure visit attendance    
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 One of the aims of this study was to compare demographic traits, personal medical 
history, and family cancer history of patients who attended and patients who missed their genetic 
testing results disclosure cancer genetic counseling visit. A better understanding of how these 
groups of patients differ may help cancer genetic counselors predict who is at higher risk to not 
attend their follow-up visit, and thus miss crucial information related to their health. In our study 
population, the patient’s sex, ethnicity, age, personal cancer history, initial visit referral 
indication, type of genetic testing ordered, and number and proportion of first and second-degree 
relatives affected with cancer did not make it more or less likely that a patient would attend their 
results disclosure visit. We had expected overlap between the factors we identified and barriers 
to initial an initial cancer genetic counseling visit or genetic testing previously identified in the 
literature. Non-White patients tend to have lower awareness of genetic testing and are more 
likely to have a type of insurance that does not cover or fully cover genetics services (Suther and 
Kiros 2009). Our study focuses on follow-up visits rather than initial visits, meaning the gap in 
initial visit uptake between White and non-White patients is bypassed. This study did not find a 
difference in genetic testing disclosure attendance rate between Asian, Hispanic, and White 
patients, suggesting that our population does not have ethnicity-based disparities in follow-up 
visit compliance. Other studies have also shown that men are underrepresented in the cancer 
genetic counseling clinic (Fraser et al. 2003). This disparity was also reflected in the low 
frequency of men in the current sample (16% of eligible patients were male, 84% female). 
However our study found no difference in results disclosure attendance rates based on sex of the 
patient. Similar to the finding for ethnicity, this may indicate that once a patient has overcome 
the barriers to a referral or initial visit to cancer genetic counseling, there is no difference or gap 
in follow-up visit compliance for men in comparison to women. Our study also did not find 
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attendance differences based on the patient’s age. Additionally, whether a person was self-
referred or physician-referred, had a personal history of cancer, or a stronger family history of 
cancer, were not predictors of follow-up visit attendance.  
One study surveyed 162 patients about their motivation for pursuing cancer genetic risk 
evaluation and found that individuals who had a personal history of cancer and higher perceived 
risk were more likely to seek cancer genetics services, however this was due to concern for their 
children rather than themselves; patients who did not have children did not have the same level 
of motivation as those who did even if they had cancer themselves (Fraser et al. 2003). This 
result is consistent with this study’s finding that patients who were parents were more likely than 
expected to attend their results disclosure appointments, but personal history of cancer did not 
have an independent impact on attendance. One study of women with breast cancer who were 
referred for genetic counseling found that having daughters was a predictor of initial genetic 
counseling appointment attendance and genetic testing uptake (Ayme et al. 2014). This study did 
not analyze the return visit attendance based on the sex of each patient’s children. While many of 
the patients in this study were referred due to potential increased risks for breast, ovarian, and 
uterine cancer, there were also patients who were referred because of a personal or family history 
of cancers that are not as sex-limited, such as colon, pancreatic, or skin cancer. 
A hypothesis of this study was that patients who were personally affected by cancer 
and/or had a higher proportion of family members who had had cancer would be more likely to 
attend their results disclosure visit, possibly out of a perceived higher personal risk for a positive 
genetic test. For patients currently undergoing cancer treatment, it is possible that the physical 
and psychological stress of treatment may cause some patients to defer genetic testing or 
receiving genetic testing results. On the other hand, for patients who are regularly coming to the 
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cancer center for treatment it might be more convenient to attend a cancer genetic counseling 
appointment in the same building or area compared to an unaffected or previously affect patient 
who would otherwise have no other reason to come to clinic. This study did not assay patient 
motivation for attending follow-up visits, but a future study should address these concerns.  
 
4.3 Limitations of this study  
 While many of the conclusions in this study are generalizable to broader cancer genetic 
counseling practice, a limitation of this retrospective chart review is that the data were collected 
from one cancer genetic counseling clinic. Genetic counseling clinics can widely differ in their 
practice strategies and protocols, and it is likely that some are very different in characteristics of 
the patient population such as socioeconomic status and demographic traits. Our patient 
population was reflective of the area local to the clinic (Table 9) (U.S. Census Bureau 2017) and 
was majority White, Hispanic, and Asian, with an underrepresentation of Black, Indian, Middle 
Eastern, and other ethnicities. As such, this study may be influenced by ethnicity-based 
disparities in genetics literacy and access to genetics providers (Christensen et al. 2010; 
Kaphingst et al. 2015; Pagán et al. 2009; Singer et al. 2004), in addition to not being 
representative of patient populations in other parts of the United States. The focus on one 
individual cancer genetic counseling clinic is this study was beneficial in ensuring our patients 
underwent a fairly uniform experience, but likely differs from other cancer genetic counseling 
clinics that may utilize different timelines of follow-up contact or different methods of 
communication (i.e. in-person, over the phone, written material, or a combination of different 
modes).  
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Table 9: Race and Hispanic-origin estimates of Orange County, CA residents for 2018 as 
reported by the United States Census Bureau. 
 
 
 
      Note: These percentages were reported by the US Census Bureau. They  
      do not add up to 100%. 
 
 
 This study identified attendance rates for different types of follow-up appointments in the 
cancer genetic counseling session, and the factors that may influence attendance. Patients who 
had genetic testing ordered at their first appointment and were scheduled for an in-person follow-
up visit for results disclosure were analyzed, but patients who either had genetic testing prior to 
the initial appointment or did not have genetic testing at the initial appointment had insufficient 
sample sizes for statistical analysis.  It would be interesting to determine whether these two 
subsets of patients also differed in attendance rate based on whether the patient is a parent, or if 
there are other factors influencing follow-up visit attendance in these groups.  
Another limitation of this study is that it cannot conclude why people attended or missed 
their visits. A survey of patients who both attended and who missed their appointments that 
examines the patients’ motivations and barriers to follow-up appointments is one potential way 
to address this question that a retrospective chart review cannot. Types of insurance for this study 
population were collected, but not analyzed, and other socioeconomic factors such as household 
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income were not collected for this study. Patient concern for cost and insurance coverage of both 
genetic counseling and genetic testing have been reported by patients as reasons they declined 
cancer genetics services, and these barriers likely also played a role in the current study 
(Anderson et al. 2012; Forman and Hall 2009). The results of the current study would be useful 
in designing a survey targeted to address the reasons patients attended or missed follow-up 
appointments. 
 
4.4 Conclusions 
In summary, this retrospective chart review identified that female patients who have 
biological children are statistically more likely than expected to attend their genetic testing 
results disclosure visit. This trend was present for male patients in our study population, but not 
statistically significant. Independently, the patient’s sex, ethnicity, age, personal cancer history, 
initial visit referral indication, type of genetic testing ordered, and proportion of first and second-
degree relatives affected with cancer did not make it more or less likely that a patient would 
attend their results disclosure visit. We found a surprising drop-off in attendance rates for 
patients who were asked to return to clinic for another follow-up visit after the results disclosure 
visit (14/82), and for patients who did not have genetic testing at the initial visit, but were 
scheduled for follow-up to revisit the option of testing after gathering information from family 
members if possible (10/33). Awareness of predictors of follow-up visit attendance can help 
genetic counselors recognize when alternate communication methods should be utilized to best 
educate and support their patients. 
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APPENDIX B 
 
 
The genes and associated disorders tested in patients who had single gene testing 
 
 
 
